Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PT404
- Development stage
- Preclinical
- Lead developer
- Peptron
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
PT404 is a long-acting, sustained-release formulation of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by Peptron using its proprietary SmartDepot™ ultrasonic spray drying technology, PT404 encapsulates tirzepatide within biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres. This formulation is designed to provide stable, sustained drug release over a monthly or bimonthly dosing interval, significantly reducing the injection frequency compared to weekly tirzepatide (Mounjaro/Zepbound). PT404 is currently in preclinical development for the treatment of type 2 diabetes and obesity, and is the subject of joint research and feasibility studies with Eli Lilly.
- Other names
- SR-Tirzepatidesustained-release tirzepatide
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on PT404.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PT404.